Logo image
Back
Oral ketamine reduces the experience of stress in people with chronic suicidality
Journal article   Peer reviewed

Oral ketamine reduces the experience of stress in people with chronic suicidality

Megan Dutton, Adem T Can, Denise Beaudequin, Emma Jensen, Monique Jones, Cyrana C Gallay, Paul E Schwenn, Jennifer K Scherman, Cian Yang, Grace Forsyth, …
Journal of Affective Disorders, Vol.300, pp.410-417
2022
DOI: https://doi.org/10.1016/j.jad.2022.01.018
PMID: 35016117
Appears in  Thompson Institute Research Collection
url
https://doi.org/10.1016/j.jad.2022.01.018View
Published Version

Abstract

Ketamine Suicidality Stress Open label Suicide prevention Ketamine Thompson Institute Special Collection
Background: Stress is prevalent in people experiencing suicidality and is a major contributor to the development of mental disorders. Evidence suggests ketamine shows capacity to reverse stress-induced brain changes. Though stress and ketamine have been explored individually for suicidality, this study is the first to examine ketamine treatment for self-reported stress in adults with chronic suicidality, building on pre-clinical evidence of ketamine's capacity to normalize stress-induced responses and contributing to our understanding of oral ketamine in clinical populations. Methods: Thirty two adult participants (22–72 years; 17 female) with chronic suicidality completed 6 weeks of active treatment, receiving low (0.5 mg/kg – 3.0 mg/kg) doses of oral ketamine once per week, with a 4-week follow-up phase, to assess the effect of ketamine on their perceived stress. Stress was measured via self-report utilizing the Depression Anxiety Stress Scale-21(DASS-21), and analysed at pre-treatment (week 0), post-treatment (week 6) and at follow-up (week 10). Results: Repeated measures ANOVA showed a significant reduction in stress (p<.001) post-treatment and Reliable Change Index calculations confirmed this to be clinically significant. Furthermore, those classified as ‘prolonged responders’ demonstrated a sustained reduction in stress at follow-up (i.e. after 4 weeks of nil ketamine). Limitations: Small sample size, open label design, expectancy, secondary analysis Conclusions: Ketamine showed the capacity to produce a robust and sustained improvement in stress symptoms, in people with chronic suicidality. Future larger, controlled studies examining treatment suitability in a range of stress related disorders are warranted.

Details

Metrics

102 Record Views
12 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Web Of Science research areas
Clinical Neurology
Psychiatry

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs from InCites

Logo image